Combating Antibiotic Resistance Through the Health Impact Fund
Boston University School of Law
Yale MacMillan Center; Centre for Applied Philosophy and Public Ethics; Centre for the Study of Mind in Nature
University of Calgary - Economics
June 22, 2011
Boston Univ. School of Law, Law and Economics Research Paper No. 11-30
The Health Impact Fund (Hollis & Pogge 2008) is an innovative financing mechanism for global drug discovery and dissemination, separating the reward for successful R&D from the market price of the drug, also known as de-linkage. Aaron Kesselheim and Kevin Outterson have recently proposed a mechanism to reimburse companies for antibiotics according to their social value, but conditioned on achieving conservation goals to limit resistance (Kesselheim & Outterson 2010, 2011). This paper will explore whether this antibiotic resistance conservation proposal can be adapted to the framework of the Health Impact Fund. If these proposals can be meshed, then antibiotics might be an interesting therapeutic class for a test of the Health Impact Fund.
Number of Pages in PDF File: 36
Keywords: health impact, antibiotic, resistance, pay-for-performanceworking papers series
Date posted: June 19, 2011 ; Last revised: November 1, 2011
© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo3 in 0.390 seconds